You are here
Dr. Stephen Rapundalo has broad experience in the life sciences with an extensive background in pharmaceutical research and development. Prior to his appointment to executive director of MichBio in April 2006, he spent almost 20 years as a senior research scientist, project manager, and group leader with Parke-Davis Pharmaceutical Research and then Pfizer, Inc., primarily in the area of cardiovascular drug discovery.
Dr. Rapundalo is a community advocate and civic leader. He formerly served as an elected member of the Ann Arbor City Council.
In his conversation with Paul Krutko, president and CEO of Ann Arbor SPARK, Rapundalo discusses the focus and impact of emerging bio companies. He also talks about the ecosystem of Ann Arbor after the closing of Pfizer, his thoughts on graduate engagement and retention, and why he thinks Ann Arbor is a great place to live and work.